Drug Profile
Imatinib - YD Global Life Science
Alternative Names: Imatinib mesylate - YD Global Life Science; YD 312Latest Information Update: 04 Jun 2022
Price :
$50
*
At a glance
- Originator YD Global Life Science
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 04 Jun 2022 Imatinib is still in phase-II trials in Diabetic macular oedema in South Korea (PO) (YD Global Life Science's pipeline, June 2022)
- 04 Jun 2022 Phase-II clinical trials in Age-related macular degeneration in South Korea (PO) (YD Global Life Science's pipeline, June 2022)
- 04 Jun 2022 Phase-II clinical trials in Diabetic retinopathy in South Korea (PO) (YD Global Life Science's pipeline, June 2022)